Dr. Kamal Dua is a Senior Lecturer in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over 12 years in the field of drug delivery systems targeting inflammatory diseases. Dr Dua is also a Node Leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr Dua researches in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 80 research articles in peer-reviewed international journals and authored or co-authored 4 books.  He is an active member of many national and international professional societiesDr Srinivas Nammi is working as Senior Lecturer in Pharmacology and Academic Course (BMedSc) at the School of Science, Western Sydney University (WSU), Australia. He holds a doctorate in Pharmaceutical Sciences, specializing in Pharmacology from Andhra University, India. Before joining the WSU, he worked at the Faculty of Pharmacy, University  of  Sydney,  after  gaining  postdoctoral  experience  as  DAAD  Fellow  at  the  University  of  Tübingen, Germany and the University of Manitoba, Canada. He has 1 international patent and has published over 80 scientific papers, 10 editorials and 3 book chapters. He is also serving as Secretary for the Australian DAAD Alumni Association.Prof Dennis Chang holds a doctorate and MSc degree in Pharmacology from the University of Sydney, Australia. His research interests include clinical and pharmacological studies of complementary medicine (CM). He is a chief investigator of several significant Phase II and III clinical trials to evaluate CM interventions (herbal medicine, yoga and Tai Chi) for the treatment of dementia, mild cognitive impairment, coronary heart disease, metabolic syndrome and type 2 diabetes. He has led numerous laboratory-based pharmacological studies of herbal medicines to evaluate pharmacokinetics/bioavailability and mechanisms of action underlying the neuro- and cardiac-protective effects of herbal medicines.Dr. Dinesh Kumar Chellappan holds PhD and Master’s degree in Pharmaceutical Sciences from Manipal University, India. He has worked on several research projects focused on inflammatory diseases with the core area in diabetes treatment and management. He is actively involved in undertaking research in chronic inflammatory pulmonary diseases, particularly developing and testing novel drug delivery systems. He has published more than 100 research articles in reputed national and international journals.Dr Gaurav Gupta is currently is working as an Associate Professor with Suresh Gyan Vihar University, Jaipur, Rajasthan, India. He holds a doctoral degree from Pacific University, Udaipur, Rajasthan, India. He has more than nine years of experience in molecular and biochemical pharmacology including phytochemistry and respiratory diseases, psychopharmacology, and cancer biology by employing experimental animal models to understand the cellular and molecular mechanism. Dr Gupta has more than 150 research and review articles in the national and international journals of repute.Dr. Trudi Collet is a leader of Innovative Medicines Group (IMG) at Kelvin Grove campus of the Queensland University of Technology and is involved in evaluating the biological properties of plant-derived bioactive compounds and extracts including their bactericidal, viricidal, and wound healing properties. She has done her PhD from the Queensland University of Technology in 2007. Earlier, she has worked as a postdoctoral fellow at the Queensland Institute of Medical Research and investigated novel serological markers for differential diagnosis of inflammatory bowel disease.

• Chapter 1. Immunopathology of respiratory diseases.- Chapter 2. Introduction to Chronic Respiratory Diseases: A Pressing Need for Novel Therapeutic Approaches.- Chapter 3. Role of Indian Herbal Medicine in the treatment of Pulmonary Diseases.- Chapter 4. Asthma-induced inflammatory responses and reversal by botanicals.- Chapter 5. Medicinal plants in targeting asthma.- Chapter 6. Incipient need of medicinal plants in targeting chronic obstructive pulmonary disease.- Chapter 7. Utilization of Natural Compounds for Treatment of Tuberculosis-I.- Chapter 8. Medicinal plants in the treatment of Tuberculosis-II.- Chapter 9. Medicinal Plants in the Treatment of tuberculosis-III.- Chapter 10.Natural compounds as versatile potential therapeutic agents of lung cancer.- Chapter 11. Exploring the potential of medicinal plants in Lung Cancer.- Chapter 12. Effect of Medicinal Plants against Lung Cancer.- Chapter 13. Medicinal Plants used in the treatment of pulmonary hypertension- I.- Chapter 14.Medicinal Plants used in the treatment of pulmonary hypertension-II.- Chapter 15. Herbal bioactives for the treatment of idiopathic pulmonary fibrosis.- Chapter 16. Medicinal Plants targeting Bronchitis.- Chapter 17. Role of medicinal plants in the treatment of pulmonary edema.- Chapter 18. Medicinal Plants Used in the Treatment of Influenza a Virus Infections.- Chapter 19. Medicinal Plants used in the treatment of influenza A virus infections.- Chapter 20. COVID-19 pandemic panic: prophylactic as well as therapeutic management with traditional ethnic phytopharmaceuticals with challenging nano-spray inhaler and advanced drug delivery system.- Chapter 21. Targeting SARS-CoV2 novel corona (COVID-19) virus infection using medicinal plants.- Chapter 22. Promising plant based bioactive natural products in combating SARS-CoV2 novel corona (COVID-19) virus infection.- Chapter 23. Medicinal plant based advanced drug delivery system for the treatment of chronic lung diseases.- Chapter 24. Medicinal Plant Based Advanced Drug Delivery System for the Treatment of Chronic Lung Diseases.- Chapter 25. Application of nanodrugs derived from active metabolites of medicinal plants for the treatment of inflammatory and lung diseases: Recent advances.

Dr. Kamal Dua is a Senior Lecturer in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over 12 years in the field of drug delivery systems targeting inflammatory diseases. Dr Dua is also a Node Leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr Dua researches in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 80 research articles in peer-reviewed international journals and authored or co-authored 4 books.  He is an active member of many national and international professional societiesDr Srinivas Nammi is working as Senior Lecturer in Pharmacology and Academic Course (BMedSc) at the School of Science, Western Sydney University (WSU), Australia. He holds a doctorate in Pharmaceutical Sciences, specializing in Pharmacology from Andhra University, India. Before joining the WSU, he worked at the Faculty of Pharmacy, University  of  Sydney,  after  gaining  postdoctoral  experience  as  DAAD  Fellow  at  the  University  of  Tübingen, Germany and the University of Manitoba, Canada. He has 1 international patent and has published over 80 scientific papers, 10 editorials and 3 book chapters. He is also serving as Secretary for the Australian DAAD Alumni Association.Prof Dennis Chang holds a doctorate and MSc degree in Pharmacology from the University of Sydney, Australia. His research interests include clinical and pharmacological studies of complementary medicine (CM). He is a chief investigator of several significant Phase II and III clinical trials to evaluate CM interventions (herbal medicine, yoga and Tai Chi) for the treatment of dementia, mild cognitive impairment, coronary heart disease, metabolic syndrome and type 2 diabetes. He has led numerous laboratory-based pharmacological studies of herbal medicines to evaluate pharmacokinetics/bioavailability and mechanisms of action underlying the neuro- and cardiac-protective effects of herbal medicines.Dr. Dinesh Kumar Chellappan holds PhD and Master’s degree in Pharmaceutical Sciences from Manipal University, India. He has worked on several research projects focused on inflammatory diseases with the core area in diabetes treatment and management. He is actively involved in undertaking research in chronic inflammatory pulmonary diseases, particularly developing and testing novel drug delivery systems. He has published more than 100 research articles in reputed national and international journals.Dr Gaurav Gupta is currently is working as an Associate Professor with Suresh Gyan Vihar University, Jaipur, Rajasthan, India. He holds a doctoral degree from Pacific University, Udaipur, Rajasthan, India. He has more than nine years of experience in molecular and biochemical pharmacology including phytochemistry and respiratory diseases, psychopharmacology, and cancer biology by employing experimental animal models to understand the cellular and molecular mechanism. Dr Gupta has more than 150 research and review articles in the national and international journals of repute.Dr. Trudi Collet is a leader of Innovative Medicines Group (IMG) at Kelvin Grove campus of the Queensland University of Technology and is involved in evaluating the biological properties of plant-derived bioactive compounds and extracts including their bactericidal, viricidal, and wound healing properties. She has done her PhD from the Queensland University of Technology in 2007. Earlier, she has worked as a postdoctoral fellow at the Queensland Institute of Medical Research and investigated novel serological markers for differential diagnosis of inflammatory bowel disease.

• Chapter 1. Immunopathology of respiratory diseases.- Chapter 2. Introduction to Chronic Respiratory Diseases: A Pressing Need for Novel Therapeutic Approaches.- Chapter 3. Role of Indian Herbal Medicine in the treatment of Pulmonary Diseases.- Chapter 4. Asthma-induced inflammatory responses and reversal by botanicals.- Chapter 5. Medicinal plants in targeting asthma.- Chapter 6. Incipient need of medicinal plants in targeting chronic obstructive pulmonary disease.- Chapter 7. Utilization of Natural Compounds for Treatment of Tuberculosis-I.- Chapter 8. Medicinal plants in the treatment of Tuberculosis-II.- Chapter 9. Medicinal Plants in the Treatment of tuberculosis-III.- Chapter 10.Natural compounds as versatile potential therapeutic agents of lung cancer.- Chapter 11. Exploring the potential of medicinal plants in Lung Cancer.- Chapter 12. Effect of Medicinal Plants against Lung Cancer.- Chapter 13. Medicinal Plants used in the treatment of pulmonary hypertension- I.- Chapter 14.Medicinal Plants used in the treatment of pulmonary hypertension-II.- Chapter 15. Herbal bioactives for the treatment of idiopathic pulmonary fibrosis.- Chapter 16. Medicinal Plants targeting Bronchitis.- Chapter 17. Role of medicinal plants in the treatment of pulmonary edema.- Chapter 18. Medicinal Plants Used in the Treatment of Influenza a Virus Infections.- Chapter 19. Medicinal Plants used in the treatment of influenza A virus infections.- Chapter 20. COVID-19 pandemic panic: prophylactic as well as therapeutic management with traditional ethnic phytopharmaceuticals with challenging nano-spray inhaler and advanced drug delivery system.- Chapter 21. Targeting SARS-CoV2 novel corona (COVID-19) virus infection using medicinal plants.- Chapter 22. Promising plant based bioactive natural products in combating SARS-CoV2 novel corona (COVID-19) virus infection.- Chapter 23. Medicinal plant based advanced drug delivery system for the treatment of chronic lung diseases.- Chapter 24. Medicinal Plant Based Advanced Drug Delivery System for the Treatment of Chronic Lung Diseases.- Chapter 25. Application of nanodrugs derived from active metabolites of medicinal plants for the treatment of inflammatory and lung diseases: Recent advances.

Dr. Kamal Dua is a Senior Lecturer in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over 12 years in the field of drug delivery systems targeting inflammatory diseases. Dr Dua is also a Node Leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr Dua researches in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 80 research articles in peer-reviewed international journals and authored or co-authored 4 books.  He is an active member of many national and international professional societiesDr Srinivas Nammi is working as Senior Lecturer in Pharmacology and Academic Course (BMedSc) at the School of Science, Western Sydney University (WSU), Australia. He holds a doctorate in Pharmaceutical Sciences, specializing in Pharmacology from Andhra University, India. Before joining the WSU, he worked at the Faculty of Pharmacy, University  of  Sydney,  after  gaining  postdoctoral  experience  as  DAAD  Fellow  at  the  University  of  Tübingen, Germany and the University of Manitoba, Canada. He has 1 international patent and has published over 80 scientific papers, 10 editorials and 3 book chapters. He is also serving as Secretary for the Australian DAAD Alumni Association.Prof Dennis Chang holds a doctorate and MSc degree in Pharmacology from the University of Sydney, Australia. His research interests include clinical and pharmacological studies of complementary medicine (CM). He is a chief investigator of several significant Phase II and III clinical trials to evaluate CM interventions (herbal medicine, yoga and Tai Chi) for the treatment of dementia, mild cognitive impairment, coronary heart disease, metabolic syndrome and type 2 diabetes. He has led numerous laboratory-based pharmacological studies of herbal medicines to evaluate pharmacokinetics/bioavailability and mechanisms of action underlying the neuro- and cardiac-protective effects of herbal medicines.Dr. Dinesh Kumar Chellappan holds PhD and Master’s degree in Pharmaceutical Sciences from Manipal University, India. He has worked on several research projects focused on inflammatory diseases with the core area in diabetes treatment and management. He is actively involved in undertaking research in chronic inflammatory pulmonary diseases, particularly developing and testing novel drug delivery systems. He has published more than 100 research articles in reputed national and international journals.Dr Gaurav Gupta is currently is working as an Associate Professor with Suresh Gyan Vihar University, Jaipur, Rajasthan, India. He holds a doctoral degree from Pacific University, Udaipur, Rajasthan, India. He has more than nine years of experience in molecular and biochemical pharmacology including phytochemistry and respiratory diseases, psychopharmacology, and cancer biology by employing experimental animal models to understand the cellular and molecular mechanism. Dr Gupta has more than 150 research and review articles in the national and international journals of repute.Dr. Trudi Collet is a leader of Innovative Medicines Group (IMG) at Kelvin Grove campus of the Queensland University of Technology and is involved in evaluating the biological properties of plant-derived bioactive compounds and extracts including their bactericidal, viricidal, and wound healing properties. She has done her PhD from the Queensland University of Technology in 2007. Earlier, she has worked as a postdoctoral fellow at the Queensland Institute of Medical Research and investigated novel serological markers for differential diagnosis of inflammatory bowel disease.

• Chapter 1. Immunopathology of respiratory diseases.- Chapter 2. Introduction to Chronic Respiratory Diseases: A Pressing Need for Novel Therapeutic Approaches.- Chapter 3. Role of Indian Herbal Medicine in the treatment of Pulmonary Diseases.- Chapter 4. Asthma-induced inflammatory responses and reversal by botanicals.- Chapter 5. Medicinal plants in targeting asthma.- Chapter 6. Incipient need of medicinal plants in targeting chronic obstructive pulmonary disease.- Chapter 7. Utilization of Natural Compounds for Treatment of Tuberculosis-I.- Chapter 8. Medicinal plants in the treatment of Tuberculosis-II.- Chapter 9. Medicinal Plants in the Treatment of tuberculosis-III.- Chapter 10.Natural compounds as versatile potential therapeutic agents of lung cancer.- Chapter 11. Exploring the potential of medicinal plants in Lung Cancer.- Chapter 12. Effect of Medicinal Plants against Lung Cancer.- Chapter 13. Medicinal Plants used in the treatment of pulmonary hypertension- I.- Chapter 14.Medicinal Plants used in the treatment of pulmonary hypertension-II.- Chapter 15. Herbal bioactives for the treatment of idiopathic pulmonary fibrosis.- Chapter 16. Medicinal Plants targeting Bronchitis.- Chapter 17. Role of medicinal plants in the treatment of pulmonary edema.- Chapter 18. Medicinal Plants Used in the Treatment of Influenza a Virus Infections.- Chapter 19. Medicinal Plants used in the treatment of influenza A virus infections.- Chapter 20. COVID-19 pandemic panic: prophylactic as well as therapeutic management with traditional ethnic phytopharmaceuticals with challenging nano-spray inhaler and advanced drug delivery system.- Chapter 21. Targeting SARS-CoV2 novel corona (COVID-19) virus infection using medicinal plants.- Chapter 22. Promising plant based bioactive natural products in combating SARS-CoV2 novel corona (COVID-19) virus infection.- Chapter 23. Medicinal plant based advanced drug delivery system for the treatment of chronic lung diseases.- Chapter 24. Medicinal Plant Based Advanced Drug Delivery System for the Treatment of Chronic Lung Diseases.- Chapter 25. Application of nanodrugs derived from active metabolites of medicinal plants for the treatment of inflammatory and lung diseases: Recent advances.